Point72 DIFC Ltd Makes New Investment in MBX Biosciences, Inc. (NYSE:MBX)

Point72 DIFC Ltd acquired a new stake in shares of MBX Biosciences, Inc. (NYSE:MBX) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 24,011 shares of the company’s stock, valued at approximately $624,000.

Other large investors have also modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in MBX Biosciences in the third quarter valued at approximately $278,000. Point72 Asset Management L.P. acquired a new position in shares of MBX Biosciences in the 3rd quarter valued at $405,000. The Manufacturers Life Insurance Company purchased a new stake in shares of MBX Biosciences during the 3rd quarter valued at $1,200,000. Maven Securities LTD acquired a new stake in shares of MBX Biosciences during the 3rd quarter worth $1,299,000. Finally, NEA Management Company LLC purchased a new position in shares of MBX Biosciences in the 3rd quarter worth $93,904,000.

MBX Biosciences Stock Up 0.3 %

Shares of NYSE MBX opened at $19.29 on Friday. MBX Biosciences, Inc. has a 1-year low of $15.31 and a 1-year high of $27.50. The stock has a 50-day moving average of $21.73.

MBX Biosciences (NYSE:MBX) last released its quarterly earnings results on Thursday, November 7th. The company reported ($2.78) EPS for the quarter, missing the consensus estimate of ($2.72) by ($0.06). On average, research analysts anticipate that MBX Biosciences, Inc. will post -13.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MBX shares. Guggenheim started coverage on MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $44.00 price target for the company. Jefferies Financial Group started coverage on MBX Biosciences in a report on Tuesday, October 8th. They set a “buy” rating and a $35.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of MBX Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They set a “buy” rating and a $40.00 price objective for the company.

Insider Transactions at MBX Biosciences

In other MBX Biosciences news, major shareholder Life Sciences X. L.P. Frazier purchased 625,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the purchase, the insider now owns 4,552,774 shares in the company, valued at $72,844,384. The trade was a 15.91 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward T. Mathers purchased 500,000 shares of MBX Biosciences stock in a transaction that occurred on Monday, September 16th. The stock was acquired at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the acquisition, the director now directly owns 3,614,486 shares of the company’s stock, valued at $57,831,776. The trade was a 16.05 % increase in their position. The disclosure for this purchase can be found here.

MBX Biosciences Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.